JCDecaux

John R. Wells; Vincent  Dessain

Case | HBS Case Collection | February 2005 (Revised June 2006)

JCDecaux

by John R. Wells and Vincent Dessain

Abstract

Describes how JCDecaux, the second largest global outdoor advertising company, became the world leader in street furniture advertising in a fast consolidating business environment. Also explains why, in the late 1990s, JCDecaux diversified its activities into billboards and transport outdoor advertising in reaction to competitor attacks. Places students in the position of Jean-Francois Decaux and his brother Jean-Charles Decaux, the sons of the founder and JC Decaux's co-CEOs who, in late 2004, explore ways to continue the success of the 73% family-owned business.

Keywords: Advertising; Global Strategy; Leadership Style; Family Ownership; Strategic Planning; Competitive Strategy; Diversification; Advertising Industry;

Language: English

Format: Print

32 pages

Educators Purchase

Citation:

Wells, John R., and Vincent Dessain. "JCDecaux." Harvard Business School Case 705-458, February 2005. (Revised June 2006.)

Related Work

Supplement | HBS Case Collection | February 2017

JCDecaux, 2016: Global Leader ... Again

John R. Wells and Gabriel Ellsworth

In 2016, JCDecaux was number one in the world in outdoor advertising. This was a far cry from the situation in 2003; at that time, JCDecaux had been unseated by Clear Channel from the number-one spot that it had held for decades, and it was fighting for second place with OUTFRONT (then owned by Viacom). Over the 12 intervening years, JCDecaux had doubled in size, building leadership positions in China, Japan, Latin America, Africa, and Russia, and in 2010, it had passed Clear Channel to lead the industry once more. Now, co-CEOs Jean-François Decaux and Jean-Charles Decaux were looking for new ways and new places to grow. After the company overtook Clear Channel in 2010, Jean-François had indicated that he believed that another doubling in size was feasible, but it would probably take a major acquisition to do so. And JCDecaux faced more pressing short-term issues. The contract for London bus shelters that the company had won with much fanfare in August 2015 was behind schedule. To make matters worse, the United Kingdom’s June 2016 “Brexit” vote to leave the European Union cast a shadow over the project, and the markets reacted negatively. By the start of November, JCDecaux’s share price had fallen 21% since the beginning of the year. Just what the economic uncertainty of Brexit would mean for global outdoor advertising in general, and U.K. outdoor advertising in particular, was not clear. Doubling in size in such an environment appeared a daunting task.

Keywords: JCDecaux; Clear Channel Outdoor; OUTFRONT Media; Lamar Advertising Company; Jean-François Decaux; Jean-Charles Decaux; outdoor advertising; street furniture; airports; billboards; bicycles; digital devices; digital marketing; bidding; Advertising; Advertising Campaigns; Acquisition; Mergers and Acquisitions; Business Growth and Maturation; Business Model; Business Organization; Family Business; For-Profit Firms; Joint Ventures; Design; Price; Profit; Revenue; Geographic Location; Geographic Scope; Global Range; Globalization; Global Strategy; Globalized Firms and Management; Multinational Firms and Management; Globalized Markets and Industries; Government Legislation; Business History; Human Resources; Laws and Statutes; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Growth Management; Marketing; Brands and Branding; Marketing Channels; Marketing Strategy; Product Marketing; Demand and Consumers; Supply and Industry; Operations; Distribution; Infrastructure; Logistics; Product; Product Design; Production; Organizational Structure; Property; Public Ownership; Renting or Rental; Problems and Challenges; Business and Community Relations; Business and Government Relations; Family and Family Relationships; Sales; Situation or Environment; Luxury; Strategy; Business Strategy; Commercialization; Competition; Competitive Advantage; Competitive Strategy; Consolidation; Corporate Strategy; Customization and Personalization; Expansion; Segmentation; Mobile Technology; Wireless Technology; Air Transportation; Bicycle Transportation; Rail Transportation; Transportation Networks; Advertising Industry; France; Paris;

Citation:
Wells, John R., and Gabriel Ellsworth. "JCDecaux, 2016: Global Leader ... Again." Harvard Business School Supplement 717-441, February 2017. View Details

Cite View Details Purchase Related
Case | HBS Case Collection | February 2005 (Revised June 2006)

JCDecaux

John R. Wells and Vincent Dessain

Describes how JCDecaux, the second largest global outdoor advertising company, became the world leader in street furniture advertising in a fast consolidating business environment. Also explains why, in the late 1990s, JCDecaux diversified its activities into billboards and transport outdoor advertising in reaction to competitor attacks. Places students in the position of Jean-Francois Decaux and his brother Jean-Charles Decaux, the sons of the founder and JC Decaux's co-CEOs who, in late 2004, explore ways to continue the success of the 73% family-owned business.

Keywords: Advertising; Global Strategy; Leadership Style; Family Ownership; Strategic Planning; Competitive Strategy; Diversification; Advertising Industry;

Citation:
Wells, John R., and Vincent Dessain. "JCDecaux." Harvard Business School Case 705-458, February 2005. (Revised June 2006.) View Details

Cite View Details Educators Purchase Related

Case | HBS Case Collection | September 2020

Minerva 2004: Discovery

John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for testing new drugs that was orders of magnitude faster than traditional approaches. Using this process, they had discovered the mechanism that caused 96% of all breast cancers and identified families of small molecule therapeutics that were effective in blocking this mechanism in live cells in the laboratory. Moreover, Bamdad did not think it would be long before the company could offer an early warning diagnostic for breast cancer, which would allow less invasive treatment of the condition. The company had filed several families of patent applications in support of these claims, but the challenge was funding. To date, Bamdad had relied on Federal Government grants and angel investors to fund the research, but the next steps would require much larger investment. Should Minerva seek to commercialize its drug development technology to help fund the riskier steps of drug development? Should it focus on a diagnostic which would make current treatments more effective? Should it license its small molecule therapeutics to one of the many well-funded companies seeking cures for cancer? Or should Bamdad raise capital to support tests in mice in order to reach the Federal Drug Administration IND (Investigational New Drug) application stage of drug discovery? This would allow clinical trials in humans, which would require more capital, but an IND would increase the value of Minerva’s intellectual capital substantially. What should Bamdad do?

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry;

Citation:

Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020. View Details

Cite View Details Educators Purchase

In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at Minerva had identified the mechanism that caused 96% of all breast cancers and had discovered a number of small molecule drugs and antibodies to block it. Funding the next stage of development had proven very difficult, but, undeterred, Bamdad had raised enough to keep her laboratory open and continue her research work. In the process, she made the startling discovery that the “cancer” mechanism she had discovered was an integral part of the production of all human embryonic stem cells, and that cancer was a result of this mechanism going awry. As a result, Minerva developed the ability to produce high-quality stem cells, which opened up a whole range of new commercial opportunities for the company, including advanced therapeutics and processes for growing and replacing human cells of all types. However, resources were limited. Where should she focus her efforts?

In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results looked promising.
CAR-T therapeutics were a new field attracting a lot of scientific interest. They involved genetically re-engineering a patient’s T-cells, a key element of the human immune system, to attack the cancer. The first CAR-T treatments for cancer were developed for the relatively small field of blood cancers, 7% of all cancers. For instance, early pioneer Kite Pharma Inc. (Kite) developed a treatment for a special type of lymphoma that only affected 7,500 patients a year. Still, the financial interest was huge, and Kite was acquired by Gilead Sciences Inc. in August 2017 for $11.9 billion. Similarly, Juno Therapeutics Inc. was acquired by Celgene Corporation for $9 billion in January 2018.
Minerva’s therapeutics targeted 96% of all breast cancers and 46% of prostate cancers, a market that was orders of magnitude larger. After 21 years, Bamdad believed that Minerva was on the threshold of something really big.
Should Bamdad sell the business and work within a larger organization? Or should she IPO and continue to develop the company’s long-term pipeline of therapeutics and diagnostics?

Faculty & Research

JCDecaux

Abstract

Citation:

About the Author

More from the Author